{"id":"NCT04270747","sponsor":"Amgen","briefTitle":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea速) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","officialTitle":"A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea速) in Subjects With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-22","primaryCompletion":"2022-07-18","completion":"2023-01-30","firstPosted":"2020-02-17","resultsPosted":"2024-01-05","lastUpdate":"2025-09-10"},"enrollment":576,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular (Wet) Age-related Macular Degeneration (AMD)"],"interventions":[{"type":"DRUG","name":"ABP 938","otherNames":[]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea速"]}],"arms":[{"label":"ABP 938-Treatment Group A","type":"EXPERIMENTAL"},{"label":"Aflibercept-Treatment Group B1","type":"ACTIVE_COMPARATOR"},{"label":"ABP 938-Treatment group B2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea速) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.","primaryOutcome":{"measure":"Mean Change From Baseline in BCVA at Week 8","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"ABP 938","deltaMin":6.4,"sd":8.18},{"arm":"Aflibercept","deltaMin":6.5,"sd":8.97}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":36},"locations":{"siteCount":118,"countries":["United States","Canada","Czechia","Estonia","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Poland","Serbia","Slovakia","South Korea","Spain"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":288},"commonTop":["Neovascular age-related macular degeneration","Conjunctival haemorrhage"]}}